| LDR | | 05936cmm uu200661Li 4500 |
| 001 | | 000000302703 |
| 005 | | 20230519171708 |
| 006 | | m o d |
| 007 | | cr |n||||||||| |
| 008 | | 140815t20142014dcua oab 100 0 eng d |
| 019 | |
▼a 884590397 |
| 020 | |
▼a 030930301X
▼q electronic bk. |
| 020 | |
▼a 9780309303019
▼q electronic bk. |
| 020 | |
▼z 9780309303002 |
| 020 | |
▼z 0309303001 |
| 035 | |
▼a (OCoLC)887933136
▼z (OCoLC)884590397 |
| 040 | |
▼a YDXCP
▼b eng
▼e rda
▼e pn
▼c YDXCP
▼d OCLCO
▼d E7B
▼d CUS
▼d N$T
▼d OCLCQ
▼d CDS
▼d 248032 |
| 049 | |
▼a K4RA |
| 050 | 4 |
▼a QH588.S83
▼b S74 2013 |
| 060 | 4 |
▼a QU 325 |
| 072 | 7 |
▼a HEA
▼x 039000
▼2 bisacsh |
| 072 | 7 |
▼a MED
▼x 014000
▼2 bisacsh |
| 072 | 7 |
▼a MED
▼x 022000
▼2 bisacsh |
| 072 | 7 |
▼a MED
▼x 112000
▼2 bisacsh |
| 072 | 7 |
▼a MED
▼x 045000
▼2 bisacsh |
| 082 | 04 |
▼a 616.02/774
▼2 23 |
| 111 | 2 |
▼a Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Unregulated Clinical Offerings (Workshop)
▼d (2013 :
▼c Washington, D.C.) |
| 245 | 10 |
▼a Stem cell therapies :
▼b opportunities for ensuring the quality and safety for clinical offerings : summary of a joint workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research /
▼c Adam C. Berger, Sarah H. Beachy, and Steve Olson, rapporteurs ; Board on Health Sciences Policy, Institute of Medicine ; Board on Life Sciences, Division on Earth and Life Studies, Institute of Medicine and National Research Council of the National Academies. |
| 264 | 1 |
▼a Washington, D.C. :
▼b The National Academies Press,
▼c [2014] |
| 264 | 4 |
▼c 짤2014 |
| 300 | |
▼a 1 online resource (xx, 87 pages) :
▼b color illustrations |
| 336 | |
▼a text
▼b txt
▼2 rdacontent |
| 337 | |
▼a computer
▼b c
▼2 rdamedia |
| 338 | |
▼a online resource
▼b cr
▼2 rdacarrier |
| 504 | |
▼a Includes bibliographical references. |
| 505 | 0 |
▼a Introduction and themes of the workshop -- Stem cell therapies: knowns and unknowns -- Patients' experiences -- Comparative regulatory and legal frameworks -- The roles of professional societies -- Moving forward. |
| 520 | |
▼a "Stem cells offer tremendous promise for advancing health and medicine. Whether being used to replace damaged cells and organs or else by supporting the body's intrinsic repair mechanisms, stem cells hold the potential to treat such debilitating conditions as Parkinson's disease, diabetes, and spinal cord injury. Clinical trials of stem cell treatments are under way in countries around the world, but the evidence base to support the medical use of stem cells remains limited. Despite this paucity of clinical evidence, consumer demand for treatments using stem cells has risen, driven in part by a lack of available treatment options for debilitating diseases as well as direct-to-consumer advertising and public portrayals of stem cell-based treatments. Clinics that offer stem cell therapies for a wide range of diseases and conditions have been established throughout the world, both in newly industrialized countries such as China, India, and Mexico and in developed countries such as the United States and various European nations. Though these therapies are often promoted as being established and effective, they generally have not received stringent regulatory oversight and have not been tested with rigorous trials designed to determine their safety and likely benefits. In the absence of substantiated claims, the potential for harm to patients - as well as to the field of stem cell research in general - may outweigh the potential benefits. To explore these issues, the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research held a workshop in November 2013. Stem Cell Therapies summarizes the workshop. Researchers, clinicians, patients, policy makers, and others from North America, Europe, and Asia met to examine the global pattern of treatments and products being offered, the range of patient experiences, and options to maximize the well-being of patients, either by protecting them from treatments that are dangerous or ineffective or by steering them toward treatments that are effective. This report discusses the current environment in which patients are receiving unregulated stem cell offerings, focusing on the treatments being offered and their risks and benefits. The report considers the evidence base for clinical application of stem cell technologies and ways to assure the quality of stem cell offerings."--Publisher's descriptions. |
| 650 | 0 |
▼a Stem cells
▼x Therapeutic use
▼v Congresses. |
| 650 | 0 |
▼a Cellular therapy
▼v Congresses. |
| 650 | 0 |
▼a Cellular therapy
▼x Law and legislation
▼v Congresses. |
| 650 | 2 |
▼a Stem Cells
▼v Congresses. |
| 650 | 7 |
▼a HEALTH & FITNESS
▼x Diseases
▼x General.
▼2 bisacsh |
| 650 | 7 |
▼a MEDICAL
▼x Clinical Medicine.
▼2 bisacsh |
| 650 | 7 |
▼a MEDICAL
▼x Diseases.
▼2 bisacsh |
| 650 | 7 |
▼a MEDICAL
▼x Evidence-Based Medicine.
▼2 bisacsh |
| 650 | 7 |
▼a MEDICAL
▼x Internal Medicine.
▼2 bisacsh |
| 655 | 4 |
▼a Electronic books. |
| 700 | 1 |
▼a Berger, Adam C.,
▼e rapporteur. |
| 700 | 1 |
▼a Beachy, Sarah H.,
▼e rapporteur. |
| 700 | 1 |
▼a Olson, Steve,
▼d 1956,
▼e rapporteur. |
| 710 | 2 |
▼a Institute of Medicine (U.S.).
▼b Board on Health Sciences Policy,
▼e issuing body. |
| 710 | 2 |
▼a National Research Council (U.S.).
▼b Board on Life Sciences,
▼e issuing body. |
| 710 | 2 |
▼a International Society for Stem Cell Research,
▼e issuing body. |
| 776 | 08 |
▼i Print version:
▼a Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Unregulated Clinical Offerings (Workshop) (2013 : Washington, D.C.).
▼t Stem cell therapies.
▼d Washington, D.C. : National Academies Press, [2014]
▼z 0309303001
▼w (OCoLC)882531315 |
| 856 | 40 |
▼3 EBSCOhost
▼u http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=867671 |
| 938 | |
▼a ebrary
▼b EBRY
▼n ebr10889070 |
| 938 | |
▼a EBSCOhost
▼b EBSC
▼n 867671 |
| 938 | |
▼a YBP Library Services
▼b YANK
▼n 11965887 |
| 990 | |
▼a 관리자 |